版本:
中国

BRIEF-FDA panel votes 18-8 to say benefits of Opana do not outweigh risks

March 15 Endo International Plc

* FDA panel 18-8 to say benefits of reformulated Opana ER do not continue to outweigh its risks; 1 member abstains from voting Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐